Status:
WITHDRAWN
Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention
Lead Sponsor:
Medicure
Collaborating Sponsors:
SCRI Development Innovations, LLC
Conditions:
Myocardial Infarction
Acute Coronary Syndromes
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether the efficacy of tirofiban (a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v. infusion during a percutaneous coronary intervention (PCI) plus two...
Eligibility Criteria
Inclusion
- Age \>18 years of age
- Scheduled to undergo PCI with an approved device
- Written informed consent
Exclusion
- Primary PCI for ST-elevation myocardial infarction (STEMI)
- Prior PCI within 30 days
- Prior GPIIb/IIIa use within 14 days
- Prior enoxaparin use within 4 days
- Prior STEMI within 30 days
- In non-elective subjects, a rising troponin defined as a most recent pre-PCI sample greater than the sample immediately preceding it, as long as the two samples are separated by four or more hours and have been analyzed in the same hospital laboratory.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01245725
Last Update
March 13 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.